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Novelty and Impact: In colorectal cancer, EMT has been described at the invasive 
margin, but it is also thought to occur at the tumor centre. We tested a novel tumor-based 
EMT score that stratified survival in stage II/III patients and associated with metastasis. 
This combined EMT score could be utilized to identify stage II/III patients at risk of 
micrometastases and who may benefit from standard adjuvant therapy.  
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ABSTRACT 
It is increasingly appreciated that host factors within the tumor centre and 
microenvironment play a key role in dictating colorectal cancer (CRC) outcomes. As 
a result, the metastatic process has now been defined as a result of epithelial-
mesenchymal transition (EMT). Establishment of the role of EMT within the tumor 
centre and its effect on the tumor microenvironment would be beneficial for prognosis 
and therapeutic intervention in CRC. The present study assessed five 
immunohistochemical EMT markers within the tumor centre on a 185 stage II/III 
CRC patient TMA.  
In 185 patients with CRC; cytoplasmic snail (HR 1.94 95% CI 1.15-3.29, p=0.012), 
and a novel combined EMT score (HR 3.86 95% CI 2.17-6.86, p<0.001) were 
associated with decreased cancer-specific survival. The combined EMT score was 
also associated with increased tumor budding (p=0.046), and systemic inflammation 
(p=0.007), as well as decreased memory T-cells within the stroma (p=0.030) and at 
the invasive margin (p=0.035). Furthermore, the combined EMT score was associated 
with cancer specific survival independent of TNM-stage (HR 4.12 95% CI 2.30-7.39, 
p<0.001). 
In conclusion, a novel combined EMT score stratifies patient’s survival in stage II/III 
CRC and associates with key factors of tumor metastasis. Therefore, the combined 
EMT score could be used to identify patients at risk of micrometastases and who may 
benefit from standard adjuvant therapy, potentially in combination with EMT 
blockade. 
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INTRODUCTION 
Colorectal cancer is the third most common cancer and second largest cause of cancer 
death in Europe and North America 1.  Even with advances in surgery and adjuvant 
treatment, five-year survival rates remain low at 60% 2. While pathological staging of 
the tumor remains the gold standard prognostic marker for colorectal cancer, a subset 
of patients within the same disease stage will have a worse outcome. Identifying these 
patients with aggressive disease who may benefit from adjuvant therapy remains an 
important clinical need. 
The metastatic process of tumor cells breaking away from the primary tumor, 
invading locally and migrating to distant sites has been defined as epithelial-
mesenchymal transition (EMT). EMT is the process of de-differentiation of epithelial 
cells into mesenchymal cells 3, an important component in normal inflammatory 
physiology. EMT can be considered to be an example of the tumor exploiting a 
physiological mechanism, characterized by a loss of tumor cell polarity and adhesion, 
increased motility and evasion of apoptosis 4. EMT is therefore thought to be one of 
the initiating and enabling steps in the invasion-metastasis cascade 4. Several well-
described molecular markers of EMT have been validated. Down-regulation of 
membrane E-cadherin is considered a hallmark of EMT 4, 5. E-cadherin is a 
transmembrane protein that regulates cell-cell adhesion, and is now considered to 
have tumor suppressive activity by maintaining cells in a non-motile, quiescent state 
6. β-catenin, a prime effector in the Wnt pathway, is another integral component of 
EMT 5. It links E-cadherin to the cytoskeleton by forming a complex and this is 
thought to support E-cadherin’s role in cell-cell adhesion 7. The loss of E-cadherin 
allows β-catenin to translocate into the nucleus and increase β-catenin-dependent gene 
transcription of pro-metastatic factors 8. Further upstream, a complex of proteins 
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regulates EMT, which includes transcription factors Snail, Fascin and Zinc-finger-
enhancing-binding-protein-1 (Zeb-1) 4, 5.  
Alterations in these markers have been associated with the presence of lymphatic and 
distant metastases in colorectal cancer resulting in poorer patient survival 4, 5. While 
the prognostic significance of the individual markers is well studied at the invasive 
margin, the significance of these markers within the tumor centre or as a combined 
EMT score to help predict the patients with aggressive disease has not been 
established. Furthermore, the interaction between EMT and components of the tumor 
microenvironment is still poorly understood 9. Therefore, the present study aims to 
examine the prognostic value of these five EMT markers within the tumor centre and 
to construct a combined EMT prognostic score to help predict patients with 
aggressive disease. The study will also establish the relationship between this EMT 
score and clinicopathological factors to establish new therapeutic targets for these 
patients.  
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MATERIALS AND METHODS 
Patient Cohort  
274 patients were retrospectively identified from a prospectively collected and 
maintained database of CRC resections performed between 1997 and 2007 in 
Glasgow Royal Infirmary who had undergone an elective, potentially curative 
resection for stage II-III CRC and were contained within a previously constructed 
tissue microarray (TMA) with four cores per patient taken from differing pathologist-
defined areas of the tumor centre. Patients who received neoadjuvant therapy or had 
died within 30 days of surgery were excluded. Ethical approval was obtained from the 
West of Scotland Research Ethics Committee.  
Clinicopathological Characteristics  
Tumors were staged using the fifth edition of the AJCC/UICC-TNM staging system 
10. Tumor differentiation was graded in accordance with Royal College of 
Pathologists 11. The presence of venous invasion was assessed using Elastica staining. 
Differentiation, margin involvement, peritoneal involvement, and necrosis were taken 
from pathology reports issued following resection. Ki67 was already available for this 
cohort using a threshold of 50%. MMR status was assessed as previously described 12. 
Patients were followed up for at least five years and date and cause of death were 
crosschecked with electronic case records.  Cancer-specific survival (CSS) was 
measured from date of surgery until date of death from CRC. 
Serum C-reactive protein (CRP) and albumin were recorded prospectively and 
measured within 30 days prior to surgery. The pre-operative systemic inflammatory 
response was defined using the modified Glasgow prognostic score (mGPS) as 
previously described 13.  
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Tumor Microenvironment Characteristics 
Stromal infiltration was assessed using tumor stroma percentage (TSP) as previously 
described 14.  The local inflammatory cell infiltrate was assessed using the Klintrup-
Makinen (KM) grade 15. The Glasgow microenvironment score (GMS) was calculated 
as previously described 16. Individual T-cell characterization was already available for 
this cohort. 
Immunohistochemistry 
An immunohistochemical analysis of 5 fully validated EMT markers was performed 
utilizing a previously constructed CRC patient TMA: (1) E-cadherin, (2) β-catenin, 
(3) Zeb-1, (4) Fascin and (5) Snail (Figure S1A). 
TMAs were dewaxed with Histoclear and rehydrated in decreasing concentrations of 
alcohol. Antigen retrieval was then performed under pressure in citrate buffer, pH6.0 
for 5 minutes (for E-cadherin, Zeb-1, fascin and snail) or in a water bath with EDTA 
buffer, pH8.0 at 96C for 50 minutes (for β-catenin). Endogenous peroxide activity 
was blocked with 3% hydrogen peroxide solution for 20 minutes (for E-cadherin, 
Zeb-1, fascin and snail) and 0.5% hydrogen peroxide solution for 30-45 minutes (for 
β-catenin). TMAs were then incubated in 10% casein (Vector Laboratories) for 2 
hours (E-cadherin) or 30 minutes (Zeb-1, fascin and snail) and 1% BSA for 30 
minutes (for β-catenin). Primary E-cadherin antibody (1:500; BD Biosciences, 
610182) and Zeb-1 (1:800; Sigma-Aldrich, HPA027524) were added at 4C overnight 
or for 2 hours at room temperature for β-catenin (1:50; BD Biosciences, 610154), 
fascin (1:100; Atlas Antibodies, HPA005723) and snail (1:50; abcam, ab53519). 
TMAs were then incubated in envision (DAKO) for 30 minutes (E-cadherin, Fascin 
and Zeb-1) or 2 hours (β-catenin) or ImmPRESS anti-goat IgG for 30 minutes (snail). 
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Antibody visualization was performed with 3,3’-diaminobenzidine (DAB; Vector 
Laboratories) until colour developed. Slides were counterstained with haematoxylin 
and dehydrated in alcohol and Histoclear. Slides were then mounted with DPX. 
Scoring Method 
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn 
Garden City, Hertfordshire, UK) at x20 magnification and visualized on Slidepath 
Digital Image Hub (Leica Biosystems, Milton Keynes, UK). Assessment of EMT 
markers was performed by a single examiner blinded to clinical data at x20 
magnification (total magnification x400) using the weighted histoscore. The weighted 
histoscore was calculated as follows: 0x% not stained + 1x% weakly stained + 2x% 
moderately stained + 3x% strongly stained. This gave a range of scores from 0 to 300 
with nuclear, cytoplasmic and membrane tumor-specific staining scored separately. 
For all EMT markers the four TMA cores were scored separately to ensure 
reproducibility and an average score taken (Figure S1B). 10% of tumors were also co-
scored by a co-investigator and the interclass correlation coefficient calculated to be 
<0.7 for all proteins. 
Statistical Analysis 
Histoscores were split into high and low expression using the median for each marker 
at each location.  SPSS (version 22) was used for statistical analysis. Pearson’s χ2 test 
assessed associations between EMT markers, clinicopathological features and the 
tumor microenvironment. Kaplan-Meier curves and log-rank analysis compared EMT 
markers and CSS. HRs and confidence intervals (CI) were calculated from univariate 
cox regression survival analysis. Multivariate cox regression survival analysis using a 
backward conditional elimination model and a significance threshold of p<0.05 was 
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performed to identify independent prognostic biomarkers. The study is reported in 
line with the REMARK guidelines 17 and significance was set as p<0.05. 
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RESULTS 
A total of 185 patients were studied that underwent a potentially curative resection for 
stage II-III CRC and had a valid score for all five EMT markers within the tumor 
centre. The patient characteristics for the cohort are shown in Table S1. The median 
follow-up for patients was 11.4 years (range 6.8-16.0) with 62 cancer deaths and 50 
non-cancer deaths.  
Firstly, the cohort was assessed for associations with CSS (Table 1). E-cadherin and 
fascin did not associate with CSS at any cellular location. Membrane beta-catenin 
trended towards associations with improved CSS (HR 0.62 95% CI 0.37-1.02, 
p=0.053, figure 1A). Conversely, zeb1 trended towards associations with decreased 
CSS in the cytoplasm (HR 1.57 95% CI 0.94-2.60, p=0.080, figure 1B). However, 
cytoplasmic snail significantly associated with decreased survival (HR 1.94 95% CI 
1.15-3.29, p=0.012, figure 1C). Next, the five markers were analyzed for correlations 
to assess if they are working together (Table S2). Strong correlations were seen 
between membrane e-cadherin and nuclear beta-catenin as expected (p<0.001).  
Cytoplasmic snail and zeb1 also correlated with membrane e-cadherin (p=0.001 and 
p=0.009) and nuclear beta catenin (p=0.010 and p=0.042). Cytoplasmic zeb1 also 
strongly correlate with cytoplasmic fascin (p=0.005). 
Therefore, membrane e-cadherin, nuclear beta-catenin and cytoplasmic fascin, snail 
and zeb1 were combined to create a combined EMT score. Patients with high 
membrane e-cadherin and low expression of all other markers were grouped as absent 
EMT, patients with low membrane e-cadherin or high expression of any of the other 
markers were grouped as low EMT and patients with low membrane e-cadherin and 
high expression of all other markers were grouped as high EMT. A high EMT score 
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was significantly associated with decreased CSS (HR 3.86 95% CI 2.17-6.86, 
p<0.001, Figure 1D). As MMR deficient tumors are known to lack aggressive 
invasive features associated with EMT and therefore could be a confounding factor; 
these patients were removed from the cohort. However, no significant effect on the 
combined EMT scores association with CSS was observed (HR 3.79 95% CI 2.02-
7.11, p<0.001) therefore all future analysis was performed utilizing the full cohort. 
Cytoplasmic snail and the combined EMT score were then assessed for associations 
with clinicopathological factors as shown in Table 2. Patients with high cytoplasmic 
snail were more likely to have received adjuvant therapy (p=0.007) and trended 
towards having a high mGPS (p=0.060). Similarly, patients with a high EMT score 
were more likely to have increased tumor budding (p=0.046) and an increased mGPS 
(p=0.007). A trend towards increased venous invasion (p=0.055) and decreased local 
inflammation was also seen (p=0.157). A high combined EMT score also showed 
increased lymph node metastasis levels, which was not seen for absent or low EMT 
scores (Figure 2A). 
To assess if the trend towards decreased inflammation was dependent on a specific 
lymphocyte population, associations were assessed as shown in Table 3. Cytoplasmic 
snail associated with decreased T regulatory cells within the stroma (p=0.006) and 
tumor centre (p=0.006). Similarly, the combined EMT score associated with 
decreased stromal T-regulatory cells (p=0.049) but also marginal memory T-cells 
(p=0.035) and stromal memory T-cells (p=0.030). When assessed for expression for 
each score, only patients with a high EMT score had decreased levels of CD8+ 
cytotoxic (Figure 2B), CD45RO+ memory (Figure 2C) and Fox3P+ regulatory 
(Figure 2D) T-cells. 
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Cytoplasmic snail and the combined EMT score were then taken forwards into 
multivariate analysis with common clinicopathological factors (Table 4). Under 
univariate analysis (n=185), TNM-stage (p<0.001), venous invasion (p<0.001), Ki67 
proliferation index (p=0.001), TSP (P=0.005), tumor budding (p<0.001), GMS 
(p=0.007), mGPS (p=0.011), cytoplasmic snail (p=0.014), and the combined EMT 
score (p<0.001) were associated with for CSS. The combined EMT score also 
associated with CSS independent of TNM-stage (HR 4.12 95% CI 2.30-7.39, 
p<0.001). 
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DISCUSSION 
The results of the present study show that both cytoplasmic snail and a novel 
combined EMT score stratify patients with stage II/III CRC by survival, with high 
expression having the worst prognosis. Furthermore, the combined EMT score is 
associated with increased tumor budding, invasion into blood vessels, and lymph node 
invasion suggesting it is a key factor in tumor metastasis. Therefore, blockade of 
EMT in stage II/III patients may be a potential therapeutic route to inhibit metastatic 
spread, allowing surgical resection of the primary tumor to be a curative procedure.  
Multiple studies have elucidated the clinical value of individual EMT markers at the 
invasive margin of CRC 18. Decreased membrane e-cadherin expression and increased 
nuclear beta-catenin expression have consistently been described as prognostic 
markers in colorectal cancer 19, 20. Furthermore, Bhangu et al. reported that reduced e-
cadherin and increased nuclear beta-catenin expression at the invasive margin can 
predict patients who will not respond to neoadjuvant therapy 21. Hao et al. also 
reported that reduced expression of membrane beta-catenin was associated with 
colorectal adenoma-carcinoma progression 22. Furthermore, the association between 
reduced membrane beta-catenin expression and poor survival has been reported 
widely 23-26.  However, increasingly, studies have disputed that EMT only occurs at 
this site.  
Kroepil et al. reported similar expression levels of e-cadherin and snail at the tumor 
centre and invasive margin 27. Kahlert et al. reported raised expressions of zeb-2 in 
both tumor centre and invasive margin compared with normal colorectal tissue and 
both were correlated with outcome 28.  Several other studies using TMAs in which the 
cores are taken from non-selected areas of the tumor, have also reported consistent 
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relationships between markers of EMT (beta-catenin, e-cadherin, zeb-1, snail and 
fascin-1) and clinical outcome 29-31. This is in agreement with the present study that 
shows high expression of cytoplasmic snail is associated with decreased survival in a 
TMA constructed from the centre of the tumor confirming that EMT marker 
alterations are observable in the tumor centre and can be used to predict prognosis. 
Furthermore, snail has value as a therapeutic target, with the snail inhibitor MRX34, 
undergoing a phase I trial in advanced cancers. The trial not only showed that the 
drug was tolerable but that it also had anti-tumor activity via EMT inhibition in 
hepatocellular carcinoma patients, suggesting it may be a suitable therapeutic for 
other EMT-related cancers 32. 
The value of EMT markers for prognosis and therapeutic intervention is further 
strengthened by the results of our combined EMT score utilizing five markers of EMT 
from the tumor centre. The combined EMT score strongly stratified patient survival 
and was independent of TNM-stage. The prognostic power of the combined score was 
far superior to that of any of the individual markers, suggesting the pathway needs to 
be assessed as a whole to fully elucidate its prognostic role in CRC. To the authors 
knowledge, this is the first combined EMT score tested for CRC. Kim et al. did report 
a combined score for EMT using nine markers in gastric cancer with similar 
associations with survival 33. However, as the current combined EMT score only uses 
five markers it may be more readily translated to the clinical setting. The combined 
EMT score also associated with well-established markers of metastasis.  Furthermore, 
associations were also seen with increased systemic inflammation along with a trend 
towards decreased local inflammation suggesting the tumor microenvironment may 
play a role in regulating EMT. 
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There has been limited studies showing that the tumor microenvironment interacts 
with the EMT process 9. It has been shown that tumor-associated macrophages 
promote the invasion-metastasis cascade 9. However, associations between EMT and 
the local inflammatory response have not been reported. In the present study 
increased EMT associates with decreased memory and regulatory T-cells at the 
margin and within the stroma. This decrease in regulatory T-cells was also seen for 
cytoplasmic snail.  This suggests that local inflammation may antagonize EMT within 
the tumor-centre, therefore as inflammation decreases EMT can increase to promote 
lymph node metastasis as seen in patients with a high EMT (Figure 2). 
In conclusion, the findings of the present study indicate that elucidating the presence 
of EMT markers together within the combined EMT score may allow selection of 
poor prognosis patients within stage II/III tumors and provides evidence that the local 
immune responses may regulate EMT at the tumor centre. The limitations of this 
study include a modest sample size and the use of tissue micro-arrays of the tumor 
core without normal tissue controls. Despite this, the results show that EMT within 
the tumor centre and this can be utilized as a prognostic score for patients with CRC 
that associates with markers of metastatic spread. Therefore, the EMT score could be 
used to identify patients at risk of micrometastases and who may benefit from 
standard adjuvant therapy, potentially combined with an EMT inhibitor. 
EMT inhibitors are still at an early stage with only a few phase II clinical trials 
underway in advanced solid tumors. The humanized monoclonal antibody, AB-16B5, 
an inhibitor of the EMT inducer secretory clusterin, is currently in a randomized 
phase II clinical trial in advanced solid tumors (NCT02412462). Similarly, MK-0646 
a novel humanized IGF1R monoclonal antibody is being evaluated in combination 
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with gemcitabine in a phase II trial for pancreatic cancer (NCT00769483). In CRC no 
clinical trials are currently active, however translational research has shown that 
metformin has promise as an inhibitor of EMT with anti-cancer activity 34.  This lack 
of CRC clinical trials suggests that a biomarker such as the combined EMT score is 
needed to stratify CRC patients for EMT inhibitor clinical trials +/- adjuvant therapy. 
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Table 1. EMT markers and cancer specific survival in patients undergoing 
elective, potentially curative resection of stage II/III colorectal cancer (n=185) 
 
 
 
  
 Nuclear Cytoplasmic Membrane/total 
 N (%) 10yr CSS P N (%) 10yr CSS P N (%) 10yr CSS P 
E cadherin 
Low expression 
High expression 
 
94 
91 
 
61 (6) 
68 (5) 
0.592  
87 
98 
 
68 (5) 
62 (5) 
0.833  
85 
100 
 
65 (5) 
65 (5) 
0.583 
Beta catenin 
Low expression 
High expression 
 
88 
97 
 
68 (5) 
62 (5) 
0.289  
90 
95 
 
61 (6) 
68 (5) 
0.460  
69 
116 
 
56 (6) 
60 (5) 
0.053 
Fascin 
Low expression 
High expression 
 
172 
13 
 
65 (4) 
67 (13) 
0.861  
133 
52 
 
66 (4) 
61 (7) 
0.675  
125 
60 
 
68 (5) 
59 (7) 
0.521 
Snail 
Low expression 
High expression 
 
97 
88 
 
65 (5) 
64 (5) 
0.876  
88 
97 
 
76 (5) 
55 (6) 
0.012  
95 
90 
 
70 (5) 
60 (6) 
0.270 
Zeb1 
Low expression 
High expression 
 
108 
77 
 
62 (5) 
69 (6) 
0.360  
91 
94 
 
71 (5) 
59 (5) 
0.080  
91 
94 
 
70 (5) 
60 (6) 
0.268 
Combined EMT Score 
Absent 
Low 
High 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
12 
160 
13 
 
100 (7) 
65 (4) 
31 (13) 
<0.001 
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Table 2. Relationship between EMT markers, clinicopathological characteristics 
and inflammatory responses in patients undergoing elective, potentially curative 
resection of stage II/III colorectal cancer (n=185). 
 
  Cytoplasmic Snail Combined EMT Score 
Low 
(n=88) 
High 
(n=97) 
P Absent 
(n=12) 
Low 
(n=160) 
High 
(n=13) 
P 
Age 
<65 
>65 
 
30 (34) 
58 (66) 
 
39 (40) 
58 (60) 
0.524  
2 (17) 
10 (83) 
 
62 (39) 
98 (61) 
 
5 (39) 
8 (61) 
0.287 
Sex 
Female 
Male 
 
42 (48) 
46 (52) 
 
42 (43) 
55 (57) 
0.546  
6 (50) 
6 (50) 
 
72 (45) 
88 (55) 
 
6 (46) 
7 (54) 
0.856 
Adjuvant 
No 
Yes 
 
68 (77) 
20 (23) 
 
57 (59) 
40 (41) 
0.007  
7 (58) 
5 (42) 
 
110 (69) 
50 (31) 
 
8 (62) 
6 (38) 
0.890 
Tumor site 
Colon (right-side) 
Colon (left-side) 
Rectum 
 
40 (45) 
21 (24) 
27 (31) 
 
37 (38) 
35 (36) 
25 (26) 
0.193  
5 (42) 
2 (16) 
5 (42) 
 
68 (42) 
48 (30) 
44 (28) 
 
4 (31) 
6 (46) 
3 (23) 
0.545 
TNM-stage 
II 
III 
 
46 (52) 
42 (48) 
 
49 (51) 
48 (49) 
0.812  
7 (58) 
5 (42) 
 
81 (51) 
79 (49) 
 
7 (54) 
6 (46) 
0.838 
Differentiation 
Mod/well 
Poor 
 
78 (89) 
10 (11) 
 
82 (84) 
15 (16) 
0.413  
12 (100) 
0 (0) 
 
136 (85) 
24 (15) 
 
12 (92) 
1 (8) 
0.122 
Venous invasion 
Absent 
Present 
 
59 (67) 
29 (33) 
 
58 (60) 
39 (40) 
0.306  
10 (83) 
2 (17) 
 
101 (63) 
59 (37) 
 
6 (46) 
7 (54) 
0.055 
Margin involvement 
No 
Yes 
 
81 (92) 
7 (8) 
 
93 (96) 
4 (4) 
0.270  
11 (92) 
1 (8) 
 
150 (94) 
10 (6) 
 
13 (100) 
0 (0) 
0.371 
Peritoneal involvement 
No 
Yes 
 
60 (68) 
28 (32) 
 
66 (68) 
31 (32) 
0.984  
9 (75) 
3 (25) 
 
108 (68) 
52 (32) 
 
9 (69) 
4 (31) 
0.771 
Mismatch repair status  
Competent 
Deficient 
 
77 (89) 
9 (11) 
 
79 (83) 
16 (17) 
0.211  
11 (92) 
1 (8) 
 
134 (86) 
22 (14) 
 
11 (85) 
2 (15) 
0.618 
Proliferation Index 
Low 
High 
 
35 (41) 
50 (59) 
 
35 (37) 
60 (63) 
0.552  
8 (67) 
4 (33) 
 
57 (37) 
99 (63) 
 
5 (42) 
7 (58) 
0.210 
Necrosis  
Low 
High 
 
45 (51) 
43 (49) 
 
56 (60) 
38 (40) 
0.252  
9 (75) 
3 (25) 
 
85 (54) 
73 (46) 
 
7 (58) 
5 (42) 
0.413 
Tumor stroma percentage 
Low 
High 
 
58 (71) 
24 (29) 
 
60 (70) 
26 (30) 
0.891  
9 (82) 
2 (18) 
 
102 (70) 
44 (30) 
 
7 (64) 
4 (36) 
0.352 
Tumor budding 
Low 
High 
 
49 (60) 
33 (40) 
 
59 (66) 
30 (34) 
0.376  
9 (82) 
2 (18) 
 
94 (63) 
54 (37) 
 
5 (42) 
7 (58) 
0.046 
Klintrup-Makinen grade 
Strong 
Weak 
 
29 (33) 
59 (67) 
 
31 (32) 
65 (68) 
0.924  
5 (42) 
7 (58) 
 
53 (33) 
106 (67) 
 
2 (15) 
11 (85) 
0.157 
GMS 
0 
1 
2 
 
29 (35) 
36 (43) 
18 (22) 
 
31 (35) 
38 (43) 
19 (22) 
0.973  
5 (46) 
4 (36) 
2 (18) 
 
53 (36) 
65 (44) 
31 (20) 
 
2 (18) 
5 (46) 
4 (36) 
0.151 
mGPS 
0 
1 
2 
 
53 (60) 
28 (32) 
7 (8) 
 
47 (48) 
35 (36) 
15 (16) 
0.060  
10 (83) 
2 (17) 
0 (0) 
 
84 (52) 
59 (37) 
17 (11) 
 
6 (46) 
2 (15) 
5 (39) 
0.007 
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Table 3. Relationship between EMT markers and local inflammatory inflitrate in 
patients undergoing elective, potentially curative resection of stage II/III 
colorectal cancer (n=185). 
 
 
  Cytoplasmic Snail Combined EMT Score 
Low 
(n=88) 
High 
(n=97) 
P Absent 
(n=12) 
Low 
(n=160) 
High 
(n=13) 
P 
CD3+ lymphocytes - Margin 
Low 
High 
 
44 (54) 
37 (46) 
 
55 (61) 
35 (39) 
0.359  
4 (40) 
6 (60) 
 
87 (58) 
62 (42) 
 
8 (67) 
4 (33) 
0.221 
CD3+ lymphocytes - Stroma 
Low 
High 
 
37 (44) 
48 (56) 
 
51 (54) 
44 (46) 
0.173  
5 (45) 
6 (55) 
 
74 (47) 
83 (53) 
 
9 (75) 
3 (25) 
0.144 
CD3+ lymphocytes - Centre 
Low 
High 
 
52 (61) 
33 (39) 
 
57 (71) 
28 (29) 
0.186  
6 (55) 
5 (45) 
 
103 (66) 
54 (34) 
 
10 (83) 
2 (17) 
0.142 
Cytotoxic T-cells - Margin 
Low 
High 
 
47 (59) 
33 (41) 
 
60 (65) 
33 (35) 
0.436  
4 (40) 
6 (60) 
 
94 (62) 
57 (38) 
 
9 (75) 
3 (25) 
0.099 
Cytotoxic T-cells - Stroma 
Low 
High 
 
57 (70) 
25 (30) 
 
74 (77) 
22 (23) 
0.254  
6 (60) 
4 (40) 
 
115 (74) 
41 (26) 
 
10 (83) 
2 (17) 
0.223 
Cytotoxic T-cells - Centre 
Low 
High 
 
55 (66) 
28 (34) 
 
73 (76) 
23 (24) 
0.149  
7 (70) 
3 (30) 
 
111 (71) 
46 (29) 
 
10 (83) 
2 (17) 
0.459 
Memory T-cells - Margin 
Low 
High 
 
45 (53) 
40 (47) 
 
55 (60) 
36 (40) 
0.315  
7 (58) 
5 (42) 
 
83 (54) 
70 (46) 
 
10 (91) 
1 (9) 
0.035 
Memory T-cells - Stroma 
Low 
High 
 
34 (39) 
53 (61) 
 
48 (51) 
47 (49) 
0.121  
6 (50) 
6 (50) 
 
67 (42) 
92 (58) 
 
9 (82) 
2 (18) 
0.030 
Memory T-cells - Centre 
Low 
High 
 
59 (68) 
28 (32) 
 
70 (74) 
25 (26) 
0.384  
8 (67) 
4 (33) 
 
111 (70) 
48 (30) 
 
10 (91) 
1 (9) 
0.215 
Tregs - Margin 
Low 
High 
 
49 (58) 
36 (42) 
 
63 (71) 
26 (29) 
0.070  
8 (67) 
4 (33) 
 
94 (62) 
57 (38) 
 
10 (91) 
1 (9) 
0.251 
Tregs - Stroma 
Low 
High 
 
44 (51) 
43 (49) 
 
65 (71) 
27 (29) 
0.006  
6 (50) 
6 (50) 
 
93 (60) 
63 (40) 
 
10 (91) 
1 (9) 
0.049 
Tregs - Centre 
Low 
High 
 
37 (43) 
50 (57) 
 
58 (63) 
34 (37) 
0.006  
6 (50) 
6 (50) 
 
80 (51) 
76 (49) 
 
9 (82) 
2 (18) 
0.141 
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Table 4.   Clinicopathological characteristics of patients undergoing elective, 
potentially curative resection of stage II/III colorectal cancer and cancer-specific 
survival (n=185) 
 
 
 Univariate HR 
(95% CI) 
P 
Clinicopathological Characteristics 
  
Age (<65/>65) 1.23 (0.91-1.66) 0.182 
Sex (Female/Male) 1.16 (0.70-1.93) 0.562 
Adjuvant Therapy (No/Yes) 0.90 (0.52-1.54) 0.696 
Tumor Site (Colon (right)/colon (left)/Rectum) 0.88 (0.64-1.20) 0.402 
BRAF status (WT/mutant) 0.86 (0.47-1.56) 0.620 
TNM-Stage (II/III) 2.50 (1.48-4.24) 0.001 
Differentiation (Moderate or well/Poor) 1.04 (0.49-2.18) 0.924 
Venous Invasion (Absent/Present) 2.74 (1.65-4.54) <0.001 
Margin Involvement (No/Yes) 1.36 (0.50-3.77) 0.546 
Peritoneal Involvement (No/Yes) 1.58 (0.95-2.62) 0.077 
Necrosis (Low/High) 1.00 (0.60-1.67) 0.999 
Mismatch Repair Status (Competent/Deficient) 1.50 (0.78-2.87) 0.229 
Ki67 proliferation Index (Low/High) 0.40 (0.24-0.67) 0.001 
Tumor Stroma Percentage (<50%/>50%) 2.16 (1.26-3.71) 0.005 
Tumor budding (yes/no) 2.73 (1.61-4.64) <0.001 
Inflammatory Characteristics 
  
Klintrup-Makinen Grade (Strong/Weak) 1.62 (0.91-2.90) 0.104 
GMS (0/1/2) 1.65 (1.15-2.37) 0.007 
mGPS (0/1/2) 1.55 (1.10-2.17) 0.011 
NLR (<5/>5) 0.76 (0.36-1.62) 0.477 
EMT markers 
  
Cytoplasmic Snail 1.94 (1.15-3.29) 0.014 
Combined EMT score 3.86 (2.17-6.86) <0.001 
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FIGURE LEGENDS 
 
Figure 1. EMT markers are associated with poor prognosis in patients with 
Stage II/II Colorectal cancer (n=185). (A-D) Kaplan Meier curves showing 
associations between cancer-specific survival and tumor-based markers of EMT: (A) 
membrane beta-catenin, (B) cytoplasmic snail, (C) cytoplasmic Zeb1 and (D) the 
combined EMT score. 
 
Figure 2. A high combined EMT score is associated with increased metastasis 
and decrease lymphocytes (n=185). (A) Amount of lymph node metastasis for each 
EMT score. (B-D) Level of (B) CD8+ T-cells, (C) memory T-cells and (D) regulatory 
T0cells for each EMT score. 
 
 
 
